AZ's ovarian cancer drug olaparib shows potential in late-stage prostate cancer
This article was originally published in Scrip
Executive Summary
AstraZeneca's oral PARP inhibitor olaparib (Lynparza), which was approved in December for women with ovarian cancer and inherited BRCA mutations, might also be able to benefit men with prostate cancer.